Big Operating Income from 2010 to 2026
| PRM Stock | CAD 14.73 0.23 1.59% |
Operating Income | First Reported 2016-12-31 | Previous Quarter -1.5 M | Current Value -1.2 M | Quarterly Volatility 1.4 M |
Check Big Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Big Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 343.3 K, Interest Expense of 438.1 K or Selling General Administrative of 344.4 K, as well as many indicators such as Price To Sales Ratio of 8.82, Dividend Yield of 0.08 or PTB Ratio of 0.81. Big financial statements analysis is a perfect complement when working with Big Pharma Valuation or Volatility modules.
Big | Operating Income |
Evaluating Big Pharma's Operating Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Big Pharma Split's fundamental strength.
Latest Big Pharma's Operating Income Growth Pattern
Below is the plot of the Operating Income of Big Pharma Split over the last few years. Operating Income is the amount of profit realized from Big Pharma Split operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Big Pharma Split is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Big Pharma's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Big Pharma's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Big Operating Income Regression Statistics
| Arithmetic Mean | 1,008,881 | |
| Coefficient Of Variation | 179.84 | |
| Mean Deviation | 1,284,849 | |
| Median | 323,221 | |
| Standard Deviation | 1,814,332 | |
| Sample Variance | 3.3T | |
| Range | 6.1M | |
| R-Value | 0.11 | |
| Mean Square Error | 3.5T | |
| R-Squared | 0.01 | |
| Significance | 0.68 | |
| Slope | 39,340 | |
| Total Sum of Squares | 52.7T |
Big Operating Income History
About Big Pharma Financial Statements
Big Pharma investors utilize fundamental indicators, such as Operating Income, to predict how Big Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | 12.1 K | 11.5 K |
Pair Trading with Big Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Big Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Big Pharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Big Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Big Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Big Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Big Pharma Split to buy it.
The correlation of Big Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Big Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Big Pharma Split moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Big Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.